hMG
Prescription fertility medicine; Not a casual peptide stack
Brief Overview: hMG contains gonadotropin activity, mainly FSH with LH activity depending on preparation. It is used in reproductive medicine to stimulate ovarian follicles or support spermatogenesis in selected endocrine contexts. Evidence lens: The evidence base belongs to fertility medicine, not wellness optimization. Monitoring is mandatory because overstimulation, multiple gestation, and sex-hormone shifts can be serious. How to read this: if you're new, don't treat hMG like a typical peptide vial. Once you're past the basics, think in terms of ultrasound, estradiol, LH/FSH, testosterone, semen analysis, and pregnancy-risk management.
- hMG, or menotropins, contains follicle-stimulating hormone activity with luteinizing hormone activity depending on the product.
- It is a prescription gonadotropin used in fertility medicine.
- hMG is a gonadotropin preparation containing FSH and LH activity, not a peptide repair or wellness compound. It belongs in fertility/endocrine therapy, where monitoring is central.
- FSH activity stimulates ovarian follicle development in females and Sertoli-cell support of spermatogenesis in males.
- LH activity can support steroidogenesis.
- The biology unfolds over weeks to months, not merely over the plasma half-life.
- It directly stimulates gonadal function through FSH/LH receptor pathways. In women this can drive follicular development; In men it can support spermatogenesis when used in appropriate endocrine contexts. The mechanism here is a plausibility map, not proof of a clinical outcome.
- Evidence is strongest in medically supervised fertility contexts such as ovulation induction, assisted reproduction, and hypogonadotropic hypogonadism.
- Claims about general optimization or post-cycle recovery require much narrower framing.
- Fertility/ART evidence is clinical and regulated, but male wellness or HPTA-stack use is a different evidence category. Do not merge labeled ART dosing with off-label male fertility protocols. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.
Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.
- Protocol 1: Fertility Restoration (Aggressive) [Clinical/Human Trial]; Route: Subcutaneous (SC); Dose: 75 IU – 150 IU; Frequency: 3 times per week; Duration: 3 to 6 months; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 2: Maintenance/HPTA Support [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC); Dose: 37.5 IU – 75 IU; Frequency: 2 times per week; Duration: Duration of suppressive cycle; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written.
- Protocol 3: MENOPUR FDA-label controlled ovarian stimulation protocol [FDA/Approved/Label]; Route: Subcutaneous injection into abdomen; Dose: 225 IU SC daily initial dose for ART protocol; Individualize after 5 days based on ovarian response; Frequency: Daily during ART stimulation; Timing: Beginning cycle day 2 or 3; Duration: Continue until adequate follicular development; Therapy should not exceed 20 days; Max: Do not exceed 450 IU daily; Titration/loading: Adjust after 5 days based on ultrasound follicular growth and serum estradiol; Do not adjust more frequently than every 2 days or by more than 150 IU per adjustment.; Status: Yes - FDA-approved label/product protocol for labeled ART/controlled ovarian stimulation indication only.
- Dose is usually expressed in IU, not micrograms. Protocols require sex, goal, baseline hormones, and monitoring because too much stimulation can be harmful. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.
- Time until steady state: about 2 to 3 days for the FSH component by label data.
- Half-life basis: Menopur labeling reports FSH elimination half-life about 11 to 13 hours after multiple dosing; LH activity is product- and patient-dependent.
- Beginner translation: This does not mean fertility response occurs in 2 to 3 days. Follicular development and spermatogenesis take much longer.
- Practical interpretation: Use endocrine and fertility monitoring rather than half-life alone: estradiol, follicles, testosterone context, semen analysis, and adverse-event surveillance.
- FSH/LH bioactivity and ovarian/testicular response matter more than simple half-life. Response often evolves over days to weeks. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.
- hCG is the most common medically relevant pairing in male hypogonadotropic contexts because it provides LH-like signaling while hMG supplies FSH activity.
- Clomiphene or enclomiphene may be used in some recovery strategies, but only in clinician-guided protocols.
- hMG is often paired with hCG in male fertility contexts or with ART protocols in female fertility care. Combining gonadotropins without monitoring can raise estradiol, ovarian hyperstimulation, or testicular side effects. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.
- Ovarian hyperstimulation (OHSS): a serious risk in women without careful monitoring, with fluid buildup in the abdomen and chest.
- Estrogen elevation: like hCG, it can raise aromatization of testosterone to estrogen, causing water retention or nipple sensitivity.
- Multiple gestation: in women it notably raises the chance of twins or triplets.
- Injection-site pain: often reported as more stinging than hCG, alongside the usual thromboembolic caution in high-risk settings.
- Risks include ovarian hyperstimulation, multiple gestation, injection reactions, estrogen-related symptoms, and endocrine overcorrection. Medical supervision is not optional in fertility contexts. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.
- Monitoring may include ultrasound, estradiol, LH/FSH, testosterone, semen analysis, inhibin B, pregnancy testing, CBC/CMP in selected contexts, and symptom review.
- OHSS warning signs require urgent medical attention.
- Monitor estradiol, ultrasound follicles in ovarian protocols, LH/FSH/testosterone/estradiol in male contexts, semen analysis when relevant, and symptoms of OHSS or estrogen excess. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.
- hMG products such as Menopur are prescription fertility medications.
- They are not over-the-counter peptides. hMG is prohibited for male athletes under anti-doping rules because it can stimulate endogenous testosterone production.
- Approved hMG products exist for specific fertility indications. Research-market hMG or non-label uses are separate from labeled ART use. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.